Screener
Charles River Laboratories CRL DSA — Goodwill impairment
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GoodwillImpairmentLoss.
The source filing: Charles River Laboratories’s 10-K, filed February 18, 2026.
- Filed
- Feb 18, 2026, 9:21 AM EST
- Fiscal year
- FY2025
- Accession
- 0001100682-26-000022
| Line item | RMS | DSA(1) | Manufacturing (2) | Total |
|---|---|---|---|---|
| December 30, 2023 | $497,474 | $1,662,434 | $935,137 | $3,095,045 |
| Acquisitions | — | 17,675 | — | 17,675 |
| Impairment | — | — | (215,000) | (215,000) |
| Foreign exchange | (734) | (44,458) | (5,920) | (51,112) |
| December 28, 2024 | 496,740 | 1,635,651 | 714,217 | 2,846,608 |
| Divestitures | — | (4,000) | — | (4,000) |
| Impairment | — | — | (165,000) | (165,000) |
| Foreign exchange | 14,104 | 46,867 | 25,674 | 86,645 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Charles River Laboratories's DSA — goodwill impairment?
- Charles River Laboratories (CRL) reported DSA — goodwill impairment of $0 in Q4 2025.
- What does DSA — goodwill impairment mean?
- The periodic charge recorded when the carrying amount of goodwill within the segment exceeds its implied fair value. This reflects a management assessment that the long-term economic value of acquired businesses has diminished.
Ask your AI about Charles River Laboratories's dsa — goodwill impairment.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude